Your browser doesn't support javascript.
loading
Multidrug resistant lncRNA profile in chemotherapeutic sensitive and resistant ovarian cancer cells.
Xu, Juan; Wu, Jiacong; Fu, Chenyang; Teng, Fang; Liu, Siyu; Dai, Chencheng; Shen, Rong; Jia, Xuemei.
Afiliação
  • Xu J; Department of Obstetrics and Gynecology, The Affiliated Obstetrics and Gynecology Hospital of Nanjing Medical University, Nanjing Maternity and Child Health Care Hospital, Nanjing, China.
  • Wu J; Nantong Maternity and Child Health Care Hospital, Nantong, China.
  • Fu C; Nanjing Medical University, Nanjing, China.
  • Teng F; Department of Obstetrics and Gynecology, The Affiliated Obstetrics and Gynecology Hospital of Nanjing Medical University, Nanjing Maternity and Child Health Care Hospital, Nanjing, China.
  • Liu S; Department of Obstetrics and Gynecology, The Affiliated Obstetrics and Gynecology Hospital of Nanjing Medical University, Nanjing Maternity and Child Health Care Hospital, Nanjing, China.
  • Dai C; Department of Obstetrics and Gynecology, The Affiliated Obstetrics and Gynecology Hospital of Nanjing Medical University, Nanjing Maternity and Child Health Care Hospital, Nanjing, China.
  • Shen R; Department of Obstetrics and Gynecology, The Affiliated Obstetrics and Gynecology Hospital of Nanjing Medical University, Nanjing Maternity and Child Health Care Hospital, Nanjing, China.
  • Jia X; Department of Obstetrics and Gynecology, The Affiliated Obstetrics and Gynecology Hospital of Nanjing Medical University, Nanjing Maternity and Child Health Care Hospital, Nanjing, China.
J Cell Physiol ; 233(6): 5034-5043, 2018 06.
Article em En | MEDLINE | ID: mdl-29219179
ABSTRACT
Most ovarian cancer patients are chemosensitive initially, but finally relapse with acquired chemoresistance. Multidrug-resistance is the extremely terrible situation. The mechanism for the acquired chemoresistance of ovarian cancer patients is still not clear. LncRNAs have been recognized as the important regulator of a variety of biological processes, including the multidrug-resistant process. Here, we carried out the lncRNA sequencing of the ovarian cancer cell line A2780 and the paxitaxel resistant cell line A2780/PTX which is also cross resistant to the cisplatin and epirubicin. Through integrating the published data with the cisplatin resistant lncRNAs in ovarian cancer cell line or ovarian cancer patients, 5 up-regulated and 21 down-regulated lncRNAs are considered as the multidrug-resistant lncRNAs. By real-time PCR analysis, we confirmed the 5 up-regulated and 4 down-regulated multidrug resistant lncRNAs were similarly changed in both the multidrug resistant ovarian cancer cell lines and the multidrug resistant colon cancer cell lines. Furthermore, we conducted the lncRNA-mRNA co-expression network to predict the potential multidrug resistant lncRNAs' targets. Interestingly, the multidrug resistant genes ABCB1, ABCB4, ABCC3, and ABCG2 are all co-expressed with lncRNA CTD-2589M5.4. Our results provide the valuable information for the understanding of the lncRNA function in the multidrug resistant process.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Biomarcadores Tumorais / Resistência a Múltiplos Medicamentos / Resistencia a Medicamentos Antineoplásicos / RNA Longo não Codificante / Antineoplásicos Tipo de estudo: Diagnostic_studies Limite: Female / Humans Idioma: En Revista: J Cell Physiol Ano de publicação: 2018 Tipo de documento: Article País de afiliação: China

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Biomarcadores Tumorais / Resistência a Múltiplos Medicamentos / Resistencia a Medicamentos Antineoplásicos / RNA Longo não Codificante / Antineoplásicos Tipo de estudo: Diagnostic_studies Limite: Female / Humans Idioma: En Revista: J Cell Physiol Ano de publicação: 2018 Tipo de documento: Article País de afiliação: China